Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Ethereum Foundation set 2026 zkEVM security targets using soundcalc. ETH also nears a multi month trendline test near $3,030.

Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Calling consciousness an "entropic engine" points to something psychologically obvious: selfhood costs energy. Maintaining a stable "me" model across time, contexts, and internal contradictions ...

On the buying side, ARK made a notable purchase of 17,386 shares of Coinbase Global Inc (PRE-REINCORPORATION) (NASDAQ:COIN) across its ARKK, ARKW, and ARKF ETFs, with a total dollar value of ...

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.